New options for the treatment of epilepsy

JAMA

Volumn 280, Issue 8, 1998, Pages 693-694

  Herman, Susan T ^a   Pedley, Timothy A ^a,b  

^a Columbia Presbyterian Medical Center ^*  (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

APLASTIC ANEMIA; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DRUG FORMULATION; DRUG MECHANISM; EPILEPSY; FOCAL EPILEPSY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PHARMACOKINETICS; PRIORITY JOURNAL; RASH; RECTAL DRUG ADMINISTRATION; SHORT SURVEY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VAGUS NERVE STIMULATION; VISUAL DISORDER;

EID: 0032569248     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.8.693     Document Type: Short Survey

References (21)

1. Blum DE. New drugs for persons with epilepsy. Adv Neurol. 1998;76:57-87.
2. Macdonald RL, Greenfield LJ Jr. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol. 1997;10:121-128.
3. Pellock JM, Brodie MJ. Felbamate: 1997 update. Epilepsia. 1997;38:1261-1264.
4. Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S45-S51.
5. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine-induced rash in children. Neurology. 1996;46:240-242.
6. Krauss GL, Johnson MA, Miller NR. Vigabatrin associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998;50:614-618.
7. Schachter SC, Saper CB. Vagus nerve stimulation. Epilepsia. 1998;39:677-686.
8. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther. 1995;67:351-384.
9. Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S59-S62.
10. Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy, I. Neurology. 1997;49:739-745.
11. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479.
12. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia. 1997;38:294-300.
13. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arch Neurol. 1995;52:989-996.
14. Motte J, Trevathan E, Arvidsson JVF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med. 1997;337:1801-1812.
15. Biton V. Preliminary open-label experience with topiramate in primary generalized seizures. Epilepsia. 1997;38(suppl 1):S42-S44.
16. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms. Epilepsia. 1997;38:1270-1274.
17. Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome. Epilepsia. 1994;35:993-998.
18. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328:29-33.
19. Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338:1869-1875.
20. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of phenytoin prodrug given i.v. or i.m. in patients. Neurology. 1990;40:456-460.
21. Devinsky O, Leppik I, Willmore LJ, et al. Safety of intravenous valproate. Ann Neurol. 1996;38:670-674.